Genetically proxied inhibition of HMG-CoA reductase and NPC1L1 was significantly associated with lower odds of breast cancer (especially ER-positive breast cancer), while genetically proxied inhibition of PCSK9 was associated with reduced risk of prostate cancer. This evidence concerns the gene PCSK9 and prostate carcinoma.